GLP-1 (Glucagon-Like Peptide-1): Research, Uses, Side Effects, and What the Latest Reviews Say

GLP-1 is a natural hormone with wide effects on blood sugar, appetite, digestion, and more. In medicine, GLP-1 receptor agonists are used to help treat type 2 diabetes and obesity, and research continues to expand into other uses and outcomes. This article stays close to the current research and focuses on what is supported, what is being studied, and what people should expect in practice.

Key takeaways

• GLP-1 helps regulate blood sugar, food intake, and digestion.
• GLP-1 receptor agonists can lower glucose and support weight loss, but nausea, stomach pain, diarrhea, and constipation are common side effects.
• Current clinical use includes type 2 diabetes and chronic weight management, with some agents also approved for other outcomes such as cardiovascular risk reduction.
• Research also points to possible effects on inflammation, cardio protection, neuroprotection, and other body systems.

What GLP-1 does in the body

GLP-1 stands for glucagon-like peptide-1. It is a hormone with broad effects. A major review in PMC describes GLP-1 as “a multifaceted hormone with broad pharmacological potential.” That review lists several core actions: glucose-dependent stimulation of insulin secretion, decreased gastric emptying, inhibition of food intake, increased natriuresis and diuresis, and modulation of rodent beta-cell proliferation.

These effects help explain why GLP-1 matters in both basic biology and clinical care. The hormone is tied to blood sugar control, appetite, and digestion. The same review also notes cardio- and neuroprotective effects, plus decreases in inflammation and apoptosis. It further says GLP-1 has implications for learning and memory, reward behavior, and palatability.

In simple terms, GLP-1 is not just a “weight loss hormone.” The research describes it as a pleiotropic hormone, meaning it acts in more than one way and may affect more than one system.

Why appetite and digestion change

Clinical summaries for patients explain that GLP-1 drugs mimic a natural hormone in the brain and gut. They affect metabolism, digestion, and appetite. One practical result is that people may feel full sooner. Some reports note that many people on GLP-1 drugs take in 25% to 50% fewer calories daily. That can support weight loss, but it can also make it harder to eat enough protein and total calories.

How GLP-1 drugs are used now

Several GLP-1 medicines are in common use. The research bundle names semaglutide, tirzepatide, liraglutide, and dulaglutide as common GLP-1 medications. These are used in injectable form, and the treatment plan depends on the person, the dose, and the target outcome.

A 2025 clinical summary for prescribers lists major approved uses and shows how quickly this field is changing. It notes that Ozempic (semaglutide) is approved for type 2 diabetes, and also to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It also says Ozempic was approved in January 2025 to reduce the risk of chronic kidney disease progression and cardiovascular death in people with type 2 diabetes and chronic kidney disease.

The same source says Wegovy is approved for chronic weight management, and that Mounjaro is approved for type 2 diabetes. It also says Mounjaro does not currently have an FDA indication for weight loss or cardiovascular disease prevention, though trials are ongoing. The source adds that oral semaglutide is part of the GLP-1 class and that newer approvals and payer rules keep changing rapidly.

What this means in practice

For clinicians and researchers, the key point is that GLP-1 medicines are no longer limited to glucose control alone. The research and prescribing summaries show a shift toward broader cardiometabolic use. Still, the exact indication matters. These drugs are not interchangeable in label claims, dose, or approved use.

Benefits supported by the research

The strongest and most consistent support in the bundle is for blood sugar control and weight reduction. UVA Health says GLP-1 meds help lower blood sugar and help people with obesity manage weight. The PMC review says GLP-1 has a role in glucose-dependent insulin secretion and inhibition of food intake, which fits those clinical effects.

Some sources also point to broader health effects. The PMC review says GLP-1 has cardio- and neuroprotective effects, and can reduce inflammation and apoptosis. A February 2026 pipeline update says obesity-related GLP-1 medicines have gained new approved uses such as secondary cardiovascular risk reduction, sleep apnea, and metabolic dysfunction-associated steatohepatitis, or MASH.

That said, the research should be read carefully. The fact that a pathway looks promising does not mean every use is proven, and not every product has the same label or evidence level. The bundle also notes that researchers are still learning about GLP-1’s other potential uses.

Weight loss is not the whole story

Weight loss is often the most visible outcome, but it is not the only one described in the sources. Appetite changes, food intake, blood sugar control, and future cardiometabolic outcomes are part of the current research picture. For some patients, the most immediate effect is feeling full sooner or eating less. For others, the change is seen in glucose numbers, medication needs, or long-term risk reduction goals.

Side effects and treatment limits

The most common side effects named in the research are nausea, stomach or belly pain, diarrhea, vomiting, constipation, and appetite changes. UVA Health says common complaints range from nausea to belly pain and diarrhea. GoodRx also lists nausea and vomiting, stomach pain, diarrhea, constipation, and appetite changes as common effects.

These side effects matter because they can affect adherence. If someone cannot tolerate the drug, the theoretical benefit does not help much. That is why patient education, dose changes, and supportive habits are often part of real-world care.

Managing side effects

UVA Health says people can ward off or manage common complaints so it is easier to stay the course. The article frames this as a practical part of treatment, not a side note. It also reminds readers that type, form, and dose depend on the treatment plan. Most people take weekly or daily injections.

The same source notes that there are no generic versions yet, which can affect access and cost. It also advises asking insurers about coverage. In other words, real-world use depends not just on pharmacology but on cost, tolerance, and logistics.

Body composition, protein, and muscle loss

One concern raised in the research is that weight loss on GLP-1 drugs may include lean mass. A supplement-company article in the bundle claims that studies show up to 25% to 40% of weight loss may come from muscle. That number is presented as a claim, not as a primary study in the bundle, so it should be treated cautiously. Even so, the broader concern is clear: appetite suppression can make it harder to eat enough protein and support muscle retention.

That same source argues that proper nutrition, quality supplements, and a solid exercise plan can help minimize muscle loss. It recommends a protein intake target of 0.7 to 1 gram per pound of body weight daily, and it describes the use of protein supplements when appetite is low. The article also mentions HMB as part of a support stack.

Because this source is promotional, its specific product claims should not be treated as settled science. Still, it highlights an important clinical issue: when appetite drops, nutrition quality becomes more important. That point is consistent with the broader GLP-1 context in the bundle.

Practical interpretation

For people using GLP-1 therapy, the most defensible takeaway is not that muscle loss is inevitable. It is that reduced intake can make nutrition harder, and that resistance training and adequate protein are worth attention. The research bundle supports concern about body composition, but it does not justify exaggerated claims about any one supplement stack.

What the pipeline suggests next

GLP-1 research is still moving fast. Prime Therapeutics’ February 2026 update says there are three GLP-1 FDA decisions expected in early to mid 2026. Those are Eli Lilly’s Mounjaro for a new cardiovascular indication in type 2 diabetes, Eli Lilly’s oral once-daily orforglipron for weight loss, and Novo Nordisk’s higher-dose 7.2 mg injectable Wegovy for weight loss.

The same update says the first GLP-1 receptor agonist for type 2 diabetes was FDA-approved 25 years ago, and that the first injectable GLP-1 for chronic weight management was approved over a decade ago. That time frame shows how long the field has been building and how quickly it is still changing.

The pipeline report also says more market growth is expected and that outcomes data remain key for judging risk and benefit. It describes holistic care as a cornerstone of treatment. That is a useful reminder for anyone reading about GLP-1 as if it were only a medication class for weight loss. The research picture is wider than that.

Where the evidence is still thin

Some of the most interesting GLP-1 claims are also the least settled. The PMC review says GLP-1 has implications for neuroprotection, learning and memory, reward behavior, and palatability. It also mentions possible roles beyond classic endocrine effects. But these are research directions, not guarantees of clinical use.

The pipeline update also makes clear that some expected approvals are still pending, and that dates may change. That matters because the field evolves quickly. A treatment landscape described in early 2026 may look different after more data and regulatory decisions arrive.

For researchers and clinicians, the best reading of the evidence is cautious. GLP-1 is a strong target with proven clinical value in type 2 diabetes and obesity. It is also a live research area where some benefits are established and others remain under study.

FAQ

What is GLP-1 in plain language?

GLP-1 is a natural hormone that helps regulate blood sugar, appetite, and digestion. In drug form, GLP-1 receptor agonists mimic that hormone.

What are the most common side effects?

The most common side effects listed in the research are nausea, vomiting, stomach or belly pain, diarrhea, constipation, and appetite changes.

Why do people feel full faster on GLP-1 drugs?

GLP-1 affects appetite and slows gastric emptying. The result can be earlier fullness and lower food intake.

Are GLP-1 drugs only for weight loss?

No. The research bundle shows approved use in type 2 diabetes, cardiovascular risk reduction in selected patients, chronic kidney disease-related risk reduction for some semaglutide products, and chronic weight management for some agents.

Do GLP-1 drugs affect muscle?

The bundle raises concern that some weight loss may come from muscle, and it also notes that low appetite can make it harder to eat enough protein. That is why nutrition and exercise are often discussed alongside treatment.